FACE Phase II (a Stage II Trial)
Stanford University · NCT07130669
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 60–89 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 1, Phase 2
- Target enrollment
- 80
- US sites recruiting
- 1
- Study start
- October 31, 2025
- Record last updated
- April 24, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
How to ensure adherence to computerized cognitive training in unsupervised circumstances (e.g., at-home, self-administered) in older adults at risk for Alzheimer's disease (AD) or AD related dementia (AD/ADRD) is understudied. The objective of the R33 study is to test a novel facial expression-based personalization engine (FPE) for monitoring and modulating real-time effective engagement, with an ultimate goal of enhancing long-term adherence in unsupervised cognitive training in older adults at risk for AD/ADRD. Here, Effective engagement is defined as the extent to which someone is actively engaged and performing with significant attention and enjoyment while training, addressing a balance between adherence and cognitive gains/plasticity from the training. Based on previous work, the hypotheses include that (1) mental fatigue revealed in facial expressions will reflect a trainee's degree of effective engagement, which can be modified by modulating task novelty; (2) the proposed FPE will ensure the effective engagement in cognitive training by monitoring trainee facial expressions and modulating training in response, promoting the trainee's long-term adherence to the training and cognitive plasticity. A Stage II intervention efficacy study will be conducted to compare effective engagement and adherence in unsupervised cognitive training between training programs with vs. without FPE in older adults at risk for AD/ADRD. The proposed FPE may assist in monitoring and improving effective engagement and adherence in older adults with unsupervised cognitive training. In the current application, FPE in a cognitive training program called speed of processing training will be tested. However, such FPE may be embedded to any computerized cognitive training in future studies to help address adherence related issues.
Being studied: Cognitive Remediation; Cognitive Remediation II
Conditions: MCI; Subjective Cognitive Decline (SCD); Mild Behavioral Impairment
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- English speaking
- Aged 60-89
- Living in a home, or independent- or assisted-living facility
- Adequate visual and hearing acuity
- Anti-depressants, antipsychotics, and/or anxiolytics have been stable for at least 7 days
- Memory medications have been stable for at least 3 months
- Absence of neurological/vascular disorder (For neurological disorders with minor symptoms check with PI on case-by-case basis)
Exclusion Criteria
- be enrolled in another intervention study aimed at improving cognition
- live in nursing home
- diagnosed with Multiple Sclerosis, TBI, chronic heart failure, Parkinson's disease, dementia
Recruiting US locations
Stanford University CogT Lab
Palo Alto, CA 94304-0000
Site contact: Daniela Buchillon-Almeida · 650-725-0581 · dbuchill@stanford.edu
Study contacts (from the official record)
- Feng Vankee Lin, PhD · 650-725-0581 · CogTLab_Stanford@stanford.edu
Similar studies in California
All healthy volunteers studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- Rialto, CA + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Lake Forest, CA + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Phase 1 Study of SBS-147 in Healthy Adults
Sparian Biosciences, Inc
- Location
- Cypress, CA
- Eligibility basics
- Ages 18–55